Key result
Lp(a)-targeted pharmacotherapies, such as antisense oligonucleotides and small interfering RNA therapeutics, significantly reduce Lp(a) levels in phase 2 clinical trials.
Why the study?
Lipoprotein(a) is an independent risk factor for ASCVD and calcific aortic valve disease with limited approved therapies, motivating an assessment of emerging targeted pharmacotherapies and phase 3 clinical trials.
Do emerging Lp(a)-targeted pharmacotherapies reduce Lp(a) levels and prevent major adverse cardiovascular events in patients with ASCVD or cardiovascular risk factors?
Do emerging Lp(a)-targeted pharmacotherapies reduce Lp(a) levels and prevent major adverse cardiovascular events in patients with ASCVD or cardiovascular risk factors?
Emerging Lp(a)-targeted therapies significantly reduce Lp(a) levels in phase 2 trials, with phase 3 trials ongoing to determine if this translates to reduced major adverse cardiovascular events.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Raygani et al. (2026) conducted a review in Atherosclerotic cardiovascular disease and calcific aortic valve disease. Lp(a)-targeted pharmacotherapies was evaluated. Lp(a)-targeted pharmacotherapies, such as antisense oligonucleotides and small interfering RNA therapeutics, significantly reduce Lp(a) levels in phase 2 clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: